The present invention describes a composition for gene therapy of the central nervous system comprising non-viral carriers of nanometric size (<;1.0 micrometer) complexed with at least one nucleic acid for purposes of gene therapy via nasal administration, having as main target the central nervous system and the processes for obtaining such carriers. The present invention belongs to the field of nanotechnology and consists of aqueous formulations that can be used in the pharmaceutical and medical fields.